Abbott Laboratories (NYSE: ABT) reported fourth quarter 2022 earnings results today. Net sales declined 12% year-over-year to $10.1 billion. Net earnings decreased 48% to $1 billion while EPS fell 47% to $0.59. Adjusted earnings were down 23% to $1.8 billion while adjusted EPS dropped 22% to $1.03. Abbott expects adjusted EPS from continuing operations to […]
Abbott Laboratories (NYSE: ABT) reported fourth quarter 2022 earnings results today. Net sales declined 12% year-over-year to $10.1 billion. Net earnings decreased 48% to $1 billion while EPS fell 47% to $0.59. Adjusted earnings were down 23% to $1.8 billion while adjusted EPS dropped 22% to $1.03. Abbott expects adjusted EPS from continuing operations to […]
Abbott Laboratories (NYSE: ABT) reported fourth quarter 2022 earnings results today.
Net sales declined 12% year-over-year to $10.1 billion.
Net earnings decreased 48% to $1 billion while EPS fell 47% to $0.59. Adjusted earnings were down 23% to $1.8 billion while adjusted EPS dropped 22% to $1.03.
Abbott expects adjusted EPS from continuing operations to be $4.30-4.50 for the full year of 2023.
